KPIs & Operating Metrics(New)
Breakdown Of AssetsCost Of Product SalesDeferred RevenueEmployee StatisticsGross Margin %Gross ProfitOpex As A % Of Total Revenue %OPEX SegregationProperty And EquipmentRevenue By Category Contract Revenue From CollaborationsRevenue By Category Contract Revenue From Collaborations AnnualRevenue By Collaborative Partners AnnualRevenue By Major CustomersRevenue By Major Customers %Revenue By Major Customers AnnualRevenue By Major Customers Annual %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %Total Bottles ShippedTotal Bottles Shipped Annual
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Gross Profit (2016 - 2025)

Rigel Pharmaceuticals has reported Gross Profit over the past 8 years, most recently at $63.8 million for Q4 2025.

  • Quarterly results put Gross Profit at $63.8 million for Q4 2025, up 23.24% from a year ago — trailing twelve months through Dec 2025 was $274.7 million (up 70.99% YoY), and the annual figure for FY2025 was $274.7 million, up 70.99%.
  • Gross Profit for Q4 2025 was $63.8 million at Rigel Pharmaceuticals, down from $64.7 million in the prior quarter.
  • Over the last five years, Gross Profit for RIGL hit a ceiling of $97.2 million in Q2 2025 and a floor of $16.6 million in Q1 2022.
  • Median Gross Profit over the past 5 years was $30.4 million (2022), compared with a mean of $40.6 million.
  • Biggest five-year swings in Gross Profit: plummeted 79.41% in 2022 and later soared 185.54% in 2025.
  • Rigel Pharmaceuticals' Gross Profit stood at $19.9 million in 2021, then surged by 155.68% to $50.9 million in 2022, then tumbled by 37.17% to $32.0 million in 2023, then skyrocketed by 61.89% to $51.8 million in 2024, then rose by 23.24% to $63.8 million in 2025.
  • The last three reported values for Gross Profit were $63.8 million (Q4 2025), $64.7 million (Q3 2025), and $97.2 million (Q2 2025) per Business Quant data.